Genetic eligibility shows up earlier in the pipeline than most plans assume

During enrollment planning, genetic eligibility is often treated as a therapy area question, settled once a program knows which organ system it targets. Genetic recruitment may also be seen as a late-phase concern, addressed when a study approaches the scale of Phase 2 or Phase 3. Today’s active trial pipeline supports neither assumption.